array:21 [
  "pii" => "X0211699509003608"
  "issn" => "02116995"
  "doi" => "10.3265/Nefrologia.2009.29.5.5400.en.full"
  "estado" => "S300"
  "fechaPublicacion" => "2009-10-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2009;29:392-6"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 8232
    "formatos" => array:3 [
      "EPUB" => 215
      "HTML" => 7255
      "PDF" => 762
    ]
  ]
  "Traduccion" => array:1 [
    "en" => array:17 [
      "pii" => "X2013251409003605"
      "issn" => "20132514"
      "doi" => "10.3265/Nefrologia.2009.29.5.5400.en.full"
      "estado" => "S300"
      "fechaPublicacion" => "2009-10-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia (English Version). 2009;29:392-6"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 4959
        "formatos" => array:3 [
          "EPUB" => 251
          "HTML" => 4060
          "PDF" => 648
        ]
      ]
      "en" => array:11 [
        "idiomaDefecto" => true
        "titulo" => "FGF23: a key player in mineral and bone disorder in CKD"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "392"
            "paginaFinal" => "396"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig1"
            "etiqueta" => "Fig. 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier España"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "40818078_f1_pag394.jpg"
                "Alto" => 579
                "Ancho" => 825
                "Tamanyo" => 39056
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "H. Komaba, M. Fukagawa"
            "autores" => array:2 [
              0 => array:2 [
                "Iniciales" => "H."
                "apellidos" => "Komaba"
              ]
              1 => array:2 [
                "Iniciales" => "M."
                "apellidos" => "Fukagawa"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X0211699509003608"
          "doi" => "10.3265/Nefrologia.2009.29.5.5400.en.full"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509003608?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409003605?idApp=UINPBA000064"
      "url" => "/20132514/0000002900000005/v0_201502091625/X2013251409003605/v0_201502091625/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X0211699509003706"
    "issn" => "02116995"
    "doi" => "10.3265/Nefrologia.2009.29.5.5449.en.full"
    "estado" => "S300"
    "fechaPublicacion" => "2009-10-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2009;29:397-403"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 6023
      "formatos" => array:3 [
        "EPUB" => 233
        "HTML" => 5276
        "PDF" => 514
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Modification of Diet in Renal Disease equation in the risk stratification of contrast induced acute kidney injury in hospital inpatients"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "397"
          "paginaFinal" => "403"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Modification of Diet in Renal Disease equation in the risk stratification of contrast induced acute kidney injury in hospital inpatients"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "409527_figure1.jpg"
              "Alto" => 384
              "Ancho" => 512
              "Tamanyo" => 19040
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "T. Erselcan, Z. Hasbek, I. Tandogan, C. Gumus, I. Akkurt"
          "autores" => array:5 [
            0 => array:2 [
              "Iniciales" => "T."
              "apellidos" => "Erselcan"
            ]
            1 => array:2 [
              "Iniciales" => "Z."
              "apellidos" => "Hasbek"
            ]
            2 => array:2 [
              "Iniciales" => "I."
              "apellidos" => "Tandogan"
            ]
            3 => array:2 [
              "Iniciales" => "C."
              "apellidos" => "Gumus"
            ]
            4 => array:2 [
              "Iniciales" => "I."
              "apellidos" => "Akkurt"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "X2013251409003703"
        "doi" => "10.3265/Nefrologia.2009.29.5.5449.en.full"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409003703?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509003706?idApp=UINPBA000064"
    "url" => "/02116995/0000002900000005/v0_201502091404/X0211699509003706/v0_201502091404/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X0211699509003616"
    "issn" => "02116995"
    "doi" => "10.3265/Nefrologia.2009.29.5.5429.en.full"
    "estado" => "S300"
    "fechaPublicacion" => "2009-10-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2009;29:382-91"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 10782
      "formatos" => array:3 [
        "EPUB" => 269
        "HTML" => 9928
        "PDF" => 585
      ]
    ]
    "es" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "El factor de crecimiento de tejido conectivo (CTGF): factor clave en el inicio y la progresión del daño renal"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "382"
          "paginaFinal" => "391"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Connective tissue growth factor (CTGF): a key factor in the onset and progression of kidney damage"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "407527_fig1.jpg"
              "Alto" => 522
              "Ancho" => 518
              "Tamanyo" => 36731
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "E. Sánchez-López, R. Rodríguez Díez, J. Rodríguez Vita, S. Rayego Mateos, R. R. Rodríguez Díez, E. Rodríguez García, C. Lavoz Barria, S. Mezzano, R. Selgas, J. Egido, A. Ortiz, Marta Ruiz Ortega"
          "autores" => array:12 [
            0 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Sánchez-López"
            ]
            1 => array:2 [
              "Iniciales" => "R."
              "apellidos" => "Rodríguez Díez"
            ]
            2 => array:2 [
              "Iniciales" => "J."
              "apellidos" => "Rodríguez Vita"
            ]
            3 => array:2 [
              "Iniciales" => "S."
              "apellidos" => "Rayego Mateos"
            ]
            4 => array:2 [
              "Iniciales" => "R. R."
              "apellidos" => "Rodríguez Díez"
            ]
            5 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Rodríguez García"
            ]
            6 => array:2 [
              "Iniciales" => "C."
              "apellidos" => "Lavoz Barria"
            ]
            7 => array:2 [
              "Iniciales" => "S."
              "apellidos" => "Mezzano"
            ]
            8 => array:2 [
              "Iniciales" => "R."
              "apellidos" => "Selgas"
            ]
            9 => array:2 [
              "Iniciales" => "J."
              "apellidos" => "Egido"
            ]
            10 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Ortiz"
            ]
            11 => array:2 [
              "nombre" => "Marta"
              "apellidos" => "Ruiz Ortega"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "X2013251409003613"
        "doi" => "10.3265/Nefrologia.2009.29.5.5429.en.full"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409003613?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509003616?idApp=UINPBA000064"
    "url" => "/02116995/0000002900000005/v0_201502091404/X0211699509003616/v0_201502091404/es/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "FGF23: a key player in mineral and bone disorder in CKD"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "392"
        "paginaFinal" => "396"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "H. Komaba, M. Fukagawa"
        "autores" => array:2 [
          0 => array:3 [
            "Iniciales" => "H."
            "apellidos" => "Komaba"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:4 [
            "Iniciales" => "M."
            "apellidos" => "Fukagawa"
            "email" => array:1 [
              0 => "fukagawa&#64;med&#46;kobe-u&#46;ac&#46;jp"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:3 [
            "entidad" => "Division of Nephrology and Kidney Center, Kobe University School of Medicine, Kobe, Kobe, Japan, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "FGF23&#58; a key player in mineral and bone disorder in CKD"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "408527_fig1.jpg"
            "Alto" => 499
            "Ancho" => 710
            "Tamanyo" => 31185
          ]
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">Disorders of mineral and bone metabolism are common complications of chronic kidney disease &#40;CKD&#41;<span class="elsevierStyleSup">1</span>&#46; Abnormal mineral metabolism occurs early in the course of CKD&#44; which can result in significant consequences even in patients not yet on dialysis<span class="elsevierStyleSup">2-4</span>&#46; Traditionally&#44; these abnormalities have been investigated mainly in association with the development of secondary hyperparathyroidism&#44; where phosphate retention&#44; hypocalcemia&#44; and a progressive decline in 1&#44;25-dihydroxyvitamin D &#91;1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D&#93;&#44; have been considered to be the main factors for abnormal parathyroid hormone &#40;PTH&#41; secretion<span class="elsevierStyleSup">5-7</span>&#46;</p><p class="elsevierStylePara">Recently&#44; a novel phosphaturic hormone FGF23 has been identified&#44; initially as a pathogenic factor in rare hypophosphatemic syndromes disorders<span class="elsevierStyleSup">8&#44;9</span>&#46; Studies since then have shown that this hormone plays an important role in normal physiology<span class="elsevierStyleSup">10</span> as well as in the pathogenesis of alterations in mineral metabolism such as that seen in patients with CKD<span class="elsevierStyleSup">11-13</span>&#46; In this brief review&#44; we summarize recent findings about the role of FGF23 in the&#160; pathogenesis of mineral and bone disorders in CKD&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">ROLE OF FGF23 IN PHOSPHATE AND VITAMIN D HOMEOSTASIS</span></p><p class="elsevierStylePara">FGF23 is a 32-kDa protein with 251 amino acids that is secreted mainly by osteocytes in bone<span class="elsevierStyleSup">14&#44;15</span>&#46; FGF23 was first cloned in mice as a new member of FGF family<span class="elsevierStyleSup">16</span> and identified as a causative humoral factor for autosomal dominant hypophosphatemic rickets&#47;osteomalacia &#40;ADHR&#41;<span class="elsevierStyleSup">8</span> and tumor-induced osteomalacia &#40;TIO&#41;<span class="elsevierStyleSup">9</span> that are characterized by severe hypophosphatemia&#44; inappropriate phosphaturia&#44; low levels of 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D&#44; and rickets or osteomalacia&#46; Dysregulated secretion of FGF23 is also involved in a number of other diseases with abnormal phosphate and vitamin D homeostasis&#44; such as X-linked hypophosphatemia &#40;XLH&#41;<span class="elsevierStyleSup">17</span>&#44; autosomal recessive hypophosphatemic rickets&#47;osteomalacia &#40;ARHR&#41;<span class="elsevierStyleSup">18</span>&#44; and McCune-Albright syndrome<span class="elsevierStyleSup">19</span>&#46;</p><p class="elsevierStylePara">In accordance with human diseases&#44; functional in vivo studies have shown that FGF23 is one of the most potent phosphatonins that induces renal phosphate wasting and reduction of 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D&#46; Administration of recombinant FGF23 results in phosphaturia and hypophosphatemia by suppressing the expression of sodium-phosphate&#160; cotransporter that mediates physiological phosphate uptake in proximal tubular epithelial cells<span class="elsevierStyleSup">20</span>&#46; Excess FGF23 also suppresses 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D via inhibition of 1&#945;-hydroxylase &#40;CYP27B1&#41; which converts 25-hydroxyvitamin D &#91;25&#40;OH&#41;D&#93; to 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D and stimulation of 24-hydroxylase &#40;CYP24&#41; which converts 1&#44;25&#40;OH&#41;<span class="elsevierStyleSup">2</span>D to more hydrophilic metabolites with lesser biological activity<span class="elsevierStyleSup">20</span>&#46;</p><p class="elsevierStylePara">In keeping with these observations&#44; transgenic mice that overexpress either wild-type or a mutant form of FGF23 that is resistant to cleavage developed hypophosphatemia&#44; low serum 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D levels&#44; and rickets and osteomalacia<span class="elsevierStyleSup">21&#44;22</span>&#46; Conversely&#44; targeted ablation of FGF23 leads to the opposite renal phenotype&#44; consisting of hyperphosphatemia and elevated production of 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D23&#46; Subsequent studies highlighted the physiologic role of FGF23 in maintaining normal serum phosphate levels in the setting of dietary phosphate variation<span class="elsevierStyleSup">10</span>&#44; although the precise mechanism by which phosphate loading mediates FGF23 production remains unknown&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">FGF23-KLOTHO AXIS</span></p><p class="elsevierStylePara">Another unique characteristic of FGF23 is that this molecule derives from bone and exerts its hormonal effects in the kidney despite the ubiquitous presence of its receptors &#40;FGFRs&#41;&#46; This is in sharp contrast to other FGF family members that are thought to regulate various cell functions at a local level<span class="elsevierStyleSup">24</span>&#46; This mystery has been progressively unraveled by a recent major breakthrough that FGF23 requires Klotho&#44; an anti-aging protein&#44; as a cofactor in FGF23-FGFR1c interaction<span class="elsevierStyleSup">25&#44;26</span>&#46; This fact clearly explains why Klotho mutant mice<span class="elsevierStyleSup">27</span> display a phenotype identical to that of FGF23 null mice<span class="elsevierStyleSup">23</span>&#44; both of which are characterized by premature agingrelated phenotypes associated with hyperphosphatemia and paradoxically high 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D levels&#46;</p><p class="elsevierStylePara">Of note&#44; Klotho is expressed in limited tissues such as the kidney&#44; parathyroid gland&#44; and pituitary gland&#46; It is intriguing that such limited expression pattern corresponds to the target tissues for FGF23 as functionally defined by the induction of early growth-responsive 1 &#40;Egr-1&#41; expression after intravenous administration of recombinant FGF23 to rats<span class="elsevierStyleSup">25</span>&#46; It is&#44; however&#44; still unclear how in the kidney FGF23 exerts its physiological effects on the proximal tubule despite the highest expression of Klotho-FGFR complexes in the distal tubule&#46; Several investigators hypothesize that FGF23 actions on the proximal tubule may be indirectly mediated by FGF23 stimulation of the distal tubule and subsequent release of paracrine factors<span class="elsevierStyleSup">28</span>&#44; but further researches are needed to confirm this attracting hypothesis&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">ELEVATED LEVELS OF FGF23 IN CKD</span></p><p class="elsevierStylePara">Insights into the role of FGF23 in mineral homeostasis have launched a new field of clinical research in CKD patients&#46; Several studies have measured circulating FGF23 levels in predialysis <span class="elsevierStyleSup">11</span> and dialysis <span class="elsevierStyleSup">29</span> patients using an enzyme-linked immunosorbent assay &#40;ELISA&#41; that detects the carboxylterminal portion of FGF23&#44; and reported progressively elevated FGF23 levels as serum creatinine or phosphate levels increase&#44; suggesting its physiologic response to chronic phosphate retention&#46; However&#44; the possibility of accumulation of carboxyl-terminal fragments due to decreased renal function cannot be excluded in these studies&#46;</p><p class="elsevierStylePara">Accordingly&#44; a subsequent study measured intact FGF23 levels in CKD patients using a sandwich ELISA system that exclusively detects full-length human FGF23&#44; and found similar increase in FGF23 levels along with decline in glomerular filtration rate &#40;GFR&#41;<span class="elsevierStyleSup">12</span>&#46; Furthermore&#44; serum FGF23 levels were negatively associated with 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D levels and maximal tubular reabsorption of phosphate &#40;TmP&#47;GFR&#41; correlated negatively with serum FGF23 levels&#44; consistent with the physiological action of FGF23 to inhibit phosphate reabsorption in the proximal tubule&#46; However&#44; patients with more advanced CKD exhibited impaired urinary phosphate excretion despite extremely high FGF23 levels&#46;</p><p class="elsevierStylePara">Taken together&#44; it is suggested that in early stage of CKD&#44; serum FGF23 is elevated to maintain normal serum phosphate levels by promoting urinary phosphate excretion&#44; but in advanced stage&#44; overt phosphate loading may overcome such compensation for decreased GFR despite markedly elevated FGF23 levels&#44; which in turn results in decreased renal production of 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D&#44; possibly thereby worsening secondary hyperparathyroidism<span class="elsevierStyleSup">30</span>&#46; Another group further supported this hypothesis by elegantly showing that increased FGF23 was an independent predictor of decreased 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D levels and the effects of renal function and hyperphosphatemia on serum 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D levels were completely extinguished by adjusting for FGF23&#44; suggesting that FGF23 is a central factor in the early pathogenesis of secondary hyperparathyroidism<span class="elsevierStyleSup">13</span>&#46;</p><p class="elsevierStylePara">Of note&#44; a recent observational study have shown that in patients who are beginning hemodialysis treatment high FGF23 levels were associated with mortality independently of serum phosphate levels and other known risk factors<span class="elsevierStyleSup">31</span>&#46; Supposing that FGF23 may indicate phosphate retention even in patients with normophosphatemia&#44; its measurements may be useful to identify which of those patients might benefit from more aggressive phosphate management&#46; Whether such strategies for the control of phosphate homeostasis would prolong survival of CKD patients is worthy of further investigation&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">FGF23 AND SECONDARY HYPERPARATHYROIDISM IN CKD</span></p><p class="elsevierStylePara">Serum FGF23 levels are progressively increased as kidney function declines and are markedly elevated once on dialysis therapy<span class="elsevierStyleSup">32&#44;33</span>&#46; Such high levels of FGF23 may be due to persistent phosphate retention or&#160; hyperphosphatemia&#44; while active vitamin D therapy has also been shown to increase serum FGF23 levels in dialysis patients<span class="elsevierStyleSup">34</span>&#46; This observation was further supported by in vivo and in vitro studies showing that 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D directly increases the production of FGF23 by osteoblasts through the vitamin D-responsive elements present in the FGF23 promoter<span class="elsevierStyleSup">35</span>&#46; &#40;Figure 1&#41;</p><p class="elsevierStylePara">In this context&#44; it is an interesting finding that in dialysis patients with secondary hyperparathyroidism high FGF23 levels may predict the future development of refractory hyperparathyroidism<span class="elsevierStyleSup">32&#44;33</span>&#46; Although the mechanism of this finding remains unclear&#44; it is possible that chronic phosphate retention as reflected by elevated FGF23 levels maycontribute to further progression of parathyroid hyperplasia&#44; because high phosphate directly stimulates PTH secretion and parathyroid cell proliferation&#46; Another possibility is that high levels of FGF23 at baseline may be a consequence of prolonged active vitamin D administration for severe hyperparathyroidism<span class="elsevierStyleSup">35</span>&#44; which may be related to future resistance to vitamin D therapy&#46;</p><p class="elsevierStylePara">Besides the above-mentioned indirect effect of FGF23 on parathyroid function via inhibition of 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D production&#44; the abundant expression of Klotho in the parathyroid suggests that FGF23 may directly affect parathyroid function<span class="elsevierStyleSup">25</span>&#46; In fact&#44; a recent study using rats with normal renal function has shown that FGF23 suppresses secretion of PTH in vivo and in vitro<span class="elsevierStyleSup">36</span>&#46; FGF23 also increases parathyroid 1&#945;-hydroxylase expression and partly thereby decreases secretion of PTH in primary cultures of bovine parathyroid cells<span class="elsevierStyleSup">37</span>&#46; Thus&#44; it is likely that FGF23 is a negative regulator of parathyroid function&#44; at least in normal physiology&#46; However&#44; in CKD patients with secondary hyperparathyroidism&#44; PTH secretion remains stimulated despite extremely high FGF23 levels<span class="elsevierStyleSup">32&#44;33</span>&#46; Such resistance of the parathyroid to high FGF23 levels in uremia should be investigated in future studies&#46;</p><p class="elsevierStylePara">Another issue of concern is a recent finding that PTH secretion is regulated in a Klotho- and&#160; Na<span class="elsevierStyleSup">&#43;</span>&#44;K<span class="elsevierStyleSup">&#43;</span>-ATPasedependent manner<span class="elsevierStyleSup">38</span>&#46; It is proposed that when extracellular calcium is low&#44; Na<span class="elsevierStyleSup">&#43;</span>&#44;K<span class="elsevierStyleSup">&#43;</span>-ATPase is quickly recruited to the plasma membrane and an electrochemical gradient created by increased Na<span class="elsevierStyleSup">&#43;</span>&#44;K<span class="elsevierStyleSup">&#43;</span>-ATPase may cause PTH release&#46; However&#44; it remains unclear how such a Klotho- and Na<span class="elsevierStyleSup">&#43;</span>&#44;K<span class="elsevierStyleSup">&#43;</span>-ATPasedependent PTH regulation interacts with the inhibitory effect of FGF23 on PTH secretion through Klotho-FGFR complexes&#46; Furthermore&#44; it is also a matter of concern whether such a complex mechanism is modulated in dialysis patients in whom phosphate retention is prevalent and hypocalcemic state is rare due to treatment with calcium-based phosphate binders and active vitamin D analogs&#46; Future studies should investigate the possible complex interaction between FGF23-&#44; Klotho- and Na<span class="elsevierStyleSup">&#43;</span>&#44;K<span class="elsevierStyleSup">&#43;</span>-ATPase-dependent pathways regulating PTH secretion and whether these complex mechanisms are modulated in the setting of CKD&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">CONCLUSION</span></p><p class="elsevierStylePara">The recent identification of FGF23 and Klotho as a physiological regulator of phosphate and vitamin D metabolism has considerably advanced our understanding of the mineral and bone disorder in CKD&#46; It is now clear that FGF23 plays a central role in the pathogenesis of altered mineral metabolism and secondary hyperparathyroidism in CKD patients&#46; FGF23 can be used not only as a biomarker for assessing phosphate retention but also as a predictor of mortality and future development of refractory hyperparathyroidism&#46; However&#44; the precise role of extremely elevated FGF23 levels in uremia still emains unclear&#44; especially as to its direct effect on parathyroid function&#46; Further elucidation of the FGF23- Klotho axis will help us to establish a more rational approach for the management of mineral and bone disorder that is associated with high burden of morbidity and mortality in CKD patients<span class="elsevierStyleSup">39&#44;40</span>&#46;</p><p class="elsevierStylePara"><a href="grande&#47;40818078&#95;f1&#95;pag394&#46;jpg" class="elsevierStyleCrossRefs"><img src="40818078_f1_pag394.jpg"></img></a></p><p class="elsevierStylePara">Figure 1&#46; </p>"
    "pdfFichero" => "P1-E23-S255-A408.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec434011"
          "palabras" => array:1 [
            0 => "Role of FGF23 in CKD"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec434012"
          "palabras" => array:1 [
            0 => "Role of FGF23 in CKD"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "El FGF23 es una hormona de reciente identificaci&#243;n que regula el metabolismo de los minerales y de la vitamina D&#46; En pacientes con insuficiencia renal cr&#243;nica &#40;IRC&#41;&#44; los niveles circulantes de FGF23 se elevan de forma progresiva para compensar la retenci&#243;n renal de fosfato persistente&#44; lo cual provoca una producci&#243;n renal reducida de 1&#44;25-dihidroxivitamina D y estimula&#44; por tanto&#44; la secreci&#243;n de la hormona paratifoidea&#46; Este hecho sugiere que su papel es crucial en la patog&#233;nesis de la homeostasis mineral alterada en la IRC&#46; Asimismo&#44; se ha demostrado recientemente que el FGF23 act&#250;a directamente en la gl&#225;ndula paratiroidea y media en la secreci&#243;n de la hormona paratiroidea en presencia del Klotho como cofactor&#44; aunque hasta el momento dichos efectos no se han confirmado en pacientes con IRC&#46; El FGF23 tambi&#233;n puede utilizarse como predictor de la mortalidad as&#237; como de un futuro desarrollo de hipertiroidismo refractario en pacientes sometidos a di&#225;lisis&#44; en los que los niveles de FGF23 son realmente elevados como reacci&#243;n al tratamiento de hiperfosfatemia y a la actividad de la vitamina D&#46; En este resumen breve se incluyen las aproximaciones m&#225;s recientes en cuanto al papel del FGF23 en la patog&#233;nesis de las alteraciones del metabolismo &#243;seo-mineral en la IRC&#46;"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara">FGF23 is a recently identified hormone regulating mineral and vitamin D metabolism&#46; In patients with chronic kidney disease &#40;CKD&#41;&#44; circulating FGF23 levels are progressively elevated to compensate for persistent phosphate retention&#44; which result in reduced renal production of 1&#44;25-dihydroxyvitamin D and thereby stimulate secretion of parathyroid hormone&#44; suggesting its critical role in the pathogenesis of altered mineral homeostasis in CKD&#46; Furthermore&#44; it has recently been shown that FGF23 directly acts on parathyroid gland and mediate secretion of parathyroid hormone in the presence of Klotho as a cofactor&#44; although such effects are not yet confirmed in patients with CKD&#46; FGF23 can also be used as a predictor of mortality as well as future development of refractory hyperparathyroidism in patients undergoing dialysis therapy&#44; where FGF23 levels are markedly elevated in response to hyperphosphatemia and active vitamin D treatment&#46; This brief review summarizes recent insights into the role of FGF23 in the pathogenesis of mineral and bone disorders in CKD&#46;</p>"
      ]
    ]
    "multimedia" => array:1 [
      0 => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "408527_fig1.jpg"
            "Alto" => 499
            "Ancho" => 710
            "Tamanyo" => 31185
          ]
        ]
      ]
    ]
    "bibliografia" => array:1 [
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:40 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Moe S, Drueke T, Cunningham J, et al. Definition, evaluation and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945-1953."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15615819" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Menon V, Greene T, Pereira AA, et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005;46:455-63. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16129207" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-33. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16246962" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000;11:1141-52. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10820180" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2002;283:F367-76 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12167586" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int 2006;70(Suppl 102):S3-7."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11062477" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001;98:6500-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11344269" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005;90:1519-24. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15613425" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14633152" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Shigematsu T, Yamashita T, Fukumoto S, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney 2004;44:250-6."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gutiérrez O, Isakova T, Rhee E, et al: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-15.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/15917335" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006;291:E38-49. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16449303" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Endocrine functions of bone in mineral metabolism regulation. Quarles LD. J Clin Invest 2008;118:3820-8."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11032749" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12711740" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006;38:1310-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17033621" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003;112:683-92. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12952917" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15040831" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004;145:3087¨C3094 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15319355" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Bai X, Miao D, Li J, et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004;145:5269-79. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15284207" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14966565" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S0168851013000432"
                          "estado" => "S300"
                          "issn" => "01688510"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 2008;237:18-27. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18058912" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17086194" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2006;281:6120-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16436388" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib27"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9363890" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib28"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Liu S, Vierthaler L, Tang W, et al. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 2008;19:2342-50. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18753255" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib29"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with endstage renal disease on hemodialysis. Kidney Int 2004;65:1943-6 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15086938" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib30"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF23 in CKD. Nephrol Dial Transplant 2005;20:1295-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15840677" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib31"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gutiérrez OM, Mannstadt M, Isakova T, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-94"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S0168851013001589"
                          "estado" => "S300"
                          "issn" => "01688510"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib32"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor- 23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005;67:1171-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15698459" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib33"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kazama JJ, Sato F, Omori K, et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005;67:1120-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15698453" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib34"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nishi H, Nii-Kono T, Nakanishi S, et al. Intravenous calcitriol therapy increases serum concentration of fibroblast growth factor 23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005;101:c94-c99. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15956805" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib35"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;17:1305-15. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16597685" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib36"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ben Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17992255" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib37"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007;195:125-31. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17911404" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib38"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Imura A, Tsuji Y, Murata M, et al. ¿-Klotho as a regulator of calcium homeostasis. Science 2007;316:1615-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17569864" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib39"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15284307" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib40"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18514987" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/0000002900000005/v0_201502091404/X0211699509003608/v0_201502091404/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35404"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Revisiones cortas"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/0000002900000005/v0_201502091404/X0211699509003608/v0_201502091404/en/P1-E23-S255-A408.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509003608?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

FGF23: a key player in mineral and bone disorder in CKD
FGF23: a key player in mineral and bone disorder in CKD
H.. Komabaa, M.. Fukagawaa
a Division of Nephrology and Kidney Center, Kobe University School of Medicine, Kobe, Kobe, Japan,
Leído
12570
Veces
se ha leído el artículo
2574
Total PDF
9996
Total HTML
Compartir estadísticas
 array:21 [
  "pii" => "X0211699509003608"
  "issn" => "02116995"
  "doi" => "10.3265/Nefrologia.2009.29.5.5400.en.full"
  "estado" => "S300"
  "fechaPublicacion" => "2009-10-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2009;29:392-6"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 8232
    "formatos" => array:3 [
      "EPUB" => 215
      "HTML" => 7255
      "PDF" => 762
    ]
  ]
  "Traduccion" => array:1 [
    "en" => array:17 [
      "pii" => "X2013251409003605"
      "issn" => "20132514"
      "doi" => "10.3265/Nefrologia.2009.29.5.5400.en.full"
      "estado" => "S300"
      "fechaPublicacion" => "2009-10-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia &#40;English Version&#41;. 2009;29:392-6"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 4959
        "formatos" => array:3 [
          "EPUB" => 251
          "HTML" => 4060
          "PDF" => 648
        ]
      ]
      "en" => array:11 [
        "idiomaDefecto" => true
        "titulo" => "FGF23&#58; a key player in mineral and bone disorder in CKD"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "392"
            "paginaFinal" => "396"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig1"
            "etiqueta" => "Fig. 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier Espa&#241;a"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "40818078_f1_pag394.jpg"
                "Alto" => 579
                "Ancho" => 825
                "Tamanyo" => 39056
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "H. Komaba, M. Fukagawa"
            "autores" => array:2 [
              0 => array:2 [
                "Iniciales" => "H."
                "apellidos" => "Komaba"
              ]
              1 => array:2 [
                "Iniciales" => "M."
                "apellidos" => "Fukagawa"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X0211699509003608"
          "doi" => "10.3265/Nefrologia.2009.29.5.5400.en.full"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509003608?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409003605?idApp=UINPBA000064"
      "url" => "/20132514/0000002900000005/v0_201502091625/X2013251409003605/v0_201502091625/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X0211699509003706"
    "issn" => "02116995"
    "doi" => "10.3265/Nefrologia.2009.29.5.5449.en.full"
    "estado" => "S300"
    "fechaPublicacion" => "2009-10-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2009;29:397-403"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 6023
      "formatos" => array:3 [
        "EPUB" => 233
        "HTML" => 5276
        "PDF" => 514
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Modification of Diet in Renal Disease equation in the risk stratification of contrast induced acute kidney injury in hospital inpatients"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "397"
          "paginaFinal" => "403"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Modification of Diet in Renal Disease equation in the risk stratification of contrast induced acute kidney injury in hospital inpatients"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "409527_figure1.jpg"
              "Alto" => 384
              "Ancho" => 512
              "Tamanyo" => 19040
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "T. Erselcan, Z. Hasbek, I. Tandogan, C. Gumus, I. Akkurt"
          "autores" => array:5 [
            0 => array:2 [
              "Iniciales" => "T."
              "apellidos" => "Erselcan"
            ]
            1 => array:2 [
              "Iniciales" => "Z."
              "apellidos" => "Hasbek"
            ]
            2 => array:2 [
              "Iniciales" => "I."
              "apellidos" => "Tandogan"
            ]
            3 => array:2 [
              "Iniciales" => "C."
              "apellidos" => "Gumus"
            ]
            4 => array:2 [
              "Iniciales" => "I."
              "apellidos" => "Akkurt"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "X2013251409003703"
        "doi" => "10.3265/Nefrologia.2009.29.5.5449.en.full"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409003703?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509003706?idApp=UINPBA000064"
    "url" => "/02116995/0000002900000005/v0_201502091404/X0211699509003706/v0_201502091404/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X0211699509003616"
    "issn" => "02116995"
    "doi" => "10.3265/Nefrologia.2009.29.5.5429.en.full"
    "estado" => "S300"
    "fechaPublicacion" => "2009-10-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2009;29:382-91"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 10782
      "formatos" => array:3 [
        "EPUB" => 269
        "HTML" => 9928
        "PDF" => 585
      ]
    ]
    "es" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "El factor de crecimiento de tejido conectivo &#40;CTGF&#41;&#58; factor clave en el inicio y la progresi&#243;n del da&#241;o renal"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "382"
          "paginaFinal" => "391"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Connective tissue growth factor &#40;CTGF&#41;&#58; a key factor in the onset and progression of kidney damage"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "407527_fig1.jpg"
              "Alto" => 522
              "Ancho" => 518
              "Tamanyo" => 36731
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "E. S&#225;nchez-L&#243;pez, R. Rodr&#237;guez D&#237;ez, J. Rodr&#237;guez Vita, S. Rayego Mateos, R. R. Rodr&#237;guez D&#237;ez, E. Rodr&#237;guez Garc&#237;a, C. Lavoz Barria, S. Mezzano, R. Selgas, J. Egido, A. Ortiz, Marta Ruiz Ortega"
          "autores" => array:12 [
            0 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "S&#225;nchez-L&#243;pez"
            ]
            1 => array:2 [
              "Iniciales" => "R."
              "apellidos" => "Rodr&#237;guez D&#237;ez"
            ]
            2 => array:2 [
              "Iniciales" => "J."
              "apellidos" => "Rodr&#237;guez Vita"
            ]
            3 => array:2 [
              "Iniciales" => "S."
              "apellidos" => "Rayego Mateos"
            ]
            4 => array:2 [
              "Iniciales" => "R. R."
              "apellidos" => "Rodr&#237;guez D&#237;ez"
            ]
            5 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Rodr&#237;guez Garc&#237;a"
            ]
            6 => array:2 [
              "Iniciales" => "C."
              "apellidos" => "Lavoz Barria"
            ]
            7 => array:2 [
              "Iniciales" => "S."
              "apellidos" => "Mezzano"
            ]
            8 => array:2 [
              "Iniciales" => "R."
              "apellidos" => "Selgas"
            ]
            9 => array:2 [
              "Iniciales" => "J."
              "apellidos" => "Egido"
            ]
            10 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Ortiz"
            ]
            11 => array:2 [
              "nombre" => "Marta"
              "apellidos" => "Ruiz Ortega"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "X2013251409003613"
        "doi" => "10.3265/Nefrologia.2009.29.5.5429.en.full"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409003613?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509003616?idApp=UINPBA000064"
    "url" => "/02116995/0000002900000005/v0_201502091404/X0211699509003616/v0_201502091404/es/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "FGF23&#58; a key player in mineral and bone disorder in CKD"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "392"
        "paginaFinal" => "396"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "H. Komaba, M. Fukagawa"
        "autores" => array:2 [
          0 => array:3 [
            "Iniciales" => "H."
            "apellidos" => "Komaba"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:4 [
            "Iniciales" => "M."
            "apellidos" => "Fukagawa"
            "email" => array:1 [
              0 => "fukagawa&#64;med&#46;kobe-u&#46;ac&#46;jp"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:3 [
            "entidad" => "Division of Nephrology and Kidney Center, Kobe University School of Medicine, Kobe, Kobe, Japan, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "FGF23&#58; a key player in mineral and bone disorder in CKD"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "408527_fig1.jpg"
            "Alto" => 499
            "Ancho" => 710
            "Tamanyo" => 31185
          ]
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">Disorders of mineral and bone metabolism are common complications of chronic kidney disease &#40;CKD&#41;<span class="elsevierStyleSup">1</span>&#46; Abnormal mineral metabolism occurs early in the course of CKD&#44; which can result in significant consequences even in patients not yet on dialysis<span class="elsevierStyleSup">2-4</span>&#46; Traditionally&#44; these abnormalities have been investigated mainly in association with the development of secondary hyperparathyroidism&#44; where phosphate retention&#44; hypocalcemia&#44; and a progressive decline in 1&#44;25-dihydroxyvitamin D &#91;1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D&#93;&#44; have been considered to be the main factors for abnormal parathyroid hormone &#40;PTH&#41; secretion<span class="elsevierStyleSup">5-7</span>&#46;</p><p class="elsevierStylePara">Recently&#44; a novel phosphaturic hormone FGF23 has been identified&#44; initially as a pathogenic factor in rare hypophosphatemic syndromes disorders<span class="elsevierStyleSup">8&#44;9</span>&#46; Studies since then have shown that this hormone plays an important role in normal physiology<span class="elsevierStyleSup">10</span> as well as in the pathogenesis of alterations in mineral metabolism such as that seen in patients with CKD<span class="elsevierStyleSup">11-13</span>&#46; In this brief review&#44; we summarize recent findings about the role of FGF23 in the&#160; pathogenesis of mineral and bone disorders in CKD&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">ROLE OF FGF23 IN PHOSPHATE AND VITAMIN D HOMEOSTASIS</span></p><p class="elsevierStylePara">FGF23 is a 32-kDa protein with 251 amino acids that is secreted mainly by osteocytes in bone<span class="elsevierStyleSup">14&#44;15</span>&#46; FGF23 was first cloned in mice as a new member of FGF family<span class="elsevierStyleSup">16</span> and identified as a causative humoral factor for autosomal dominant hypophosphatemic rickets&#47;osteomalacia &#40;ADHR&#41;<span class="elsevierStyleSup">8</span> and tumor-induced osteomalacia &#40;TIO&#41;<span class="elsevierStyleSup">9</span> that are characterized by severe hypophosphatemia&#44; inappropriate phosphaturia&#44; low levels of 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D&#44; and rickets or osteomalacia&#46; Dysregulated secretion of FGF23 is also involved in a number of other diseases with abnormal phosphate and vitamin D homeostasis&#44; such as X-linked hypophosphatemia &#40;XLH&#41;<span class="elsevierStyleSup">17</span>&#44; autosomal recessive hypophosphatemic rickets&#47;osteomalacia &#40;ARHR&#41;<span class="elsevierStyleSup">18</span>&#44; and McCune-Albright syndrome<span class="elsevierStyleSup">19</span>&#46;</p><p class="elsevierStylePara">In accordance with human diseases&#44; functional in vivo studies have shown that FGF23 is one of the most potent phosphatonins that induces renal phosphate wasting and reduction of 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D&#46; Administration of recombinant FGF23 results in phosphaturia and hypophosphatemia by suppressing the expression of sodium-phosphate&#160; cotransporter that mediates physiological phosphate uptake in proximal tubular epithelial cells<span class="elsevierStyleSup">20</span>&#46; Excess FGF23 also suppresses 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D via inhibition of 1&#945;-hydroxylase &#40;CYP27B1&#41; which converts 25-hydroxyvitamin D &#91;25&#40;OH&#41;D&#93; to 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D and stimulation of 24-hydroxylase &#40;CYP24&#41; which converts 1&#44;25&#40;OH&#41;<span class="elsevierStyleSup">2</span>D to more hydrophilic metabolites with lesser biological activity<span class="elsevierStyleSup">20</span>&#46;</p><p class="elsevierStylePara">In keeping with these observations&#44; transgenic mice that overexpress either wild-type or a mutant form of FGF23 that is resistant to cleavage developed hypophosphatemia&#44; low serum 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D levels&#44; and rickets and osteomalacia<span class="elsevierStyleSup">21&#44;22</span>&#46; Conversely&#44; targeted ablation of FGF23 leads to the opposite renal phenotype&#44; consisting of hyperphosphatemia and elevated production of 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D23&#46; Subsequent studies highlighted the physiologic role of FGF23 in maintaining normal serum phosphate levels in the setting of dietary phosphate variation<span class="elsevierStyleSup">10</span>&#44; although the precise mechanism by which phosphate loading mediates FGF23 production remains unknown&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">FGF23-KLOTHO AXIS</span></p><p class="elsevierStylePara">Another unique characteristic of FGF23 is that this molecule derives from bone and exerts its hormonal effects in the kidney despite the ubiquitous presence of its receptors &#40;FGFRs&#41;&#46; This is in sharp contrast to other FGF family members that are thought to regulate various cell functions at a local level<span class="elsevierStyleSup">24</span>&#46; This mystery has been progressively unraveled by a recent major breakthrough that FGF23 requires Klotho&#44; an anti-aging protein&#44; as a cofactor in FGF23-FGFR1c interaction<span class="elsevierStyleSup">25&#44;26</span>&#46; This fact clearly explains why Klotho mutant mice<span class="elsevierStyleSup">27</span> display a phenotype identical to that of FGF23 null mice<span class="elsevierStyleSup">23</span>&#44; both of which are characterized by premature agingrelated phenotypes associated with hyperphosphatemia and paradoxically high 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D levels&#46;</p><p class="elsevierStylePara">Of note&#44; Klotho is expressed in limited tissues such as the kidney&#44; parathyroid gland&#44; and pituitary gland&#46; It is intriguing that such limited expression pattern corresponds to the target tissues for FGF23 as functionally defined by the induction of early growth-responsive 1 &#40;Egr-1&#41; expression after intravenous administration of recombinant FGF23 to rats<span class="elsevierStyleSup">25</span>&#46; It is&#44; however&#44; still unclear how in the kidney FGF23 exerts its physiological effects on the proximal tubule despite the highest expression of Klotho-FGFR complexes in the distal tubule&#46; Several investigators hypothesize that FGF23 actions on the proximal tubule may be indirectly mediated by FGF23 stimulation of the distal tubule and subsequent release of paracrine factors<span class="elsevierStyleSup">28</span>&#44; but further researches are needed to confirm this attracting hypothesis&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">ELEVATED LEVELS OF FGF23 IN CKD</span></p><p class="elsevierStylePara">Insights into the role of FGF23 in mineral homeostasis have launched a new field of clinical research in CKD patients&#46; Several studies have measured circulating FGF23 levels in predialysis <span class="elsevierStyleSup">11</span> and dialysis <span class="elsevierStyleSup">29</span> patients using an enzyme-linked immunosorbent assay &#40;ELISA&#41; that detects the carboxylterminal portion of FGF23&#44; and reported progressively elevated FGF23 levels as serum creatinine or phosphate levels increase&#44; suggesting its physiologic response to chronic phosphate retention&#46; However&#44; the possibility of accumulation of carboxyl-terminal fragments due to decreased renal function cannot be excluded in these studies&#46;</p><p class="elsevierStylePara">Accordingly&#44; a subsequent study measured intact FGF23 levels in CKD patients using a sandwich ELISA system that exclusively detects full-length human FGF23&#44; and found similar increase in FGF23 levels along with decline in glomerular filtration rate &#40;GFR&#41;<span class="elsevierStyleSup">12</span>&#46; Furthermore&#44; serum FGF23 levels were negatively associated with 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D levels and maximal tubular reabsorption of phosphate &#40;TmP&#47;GFR&#41; correlated negatively with serum FGF23 levels&#44; consistent with the physiological action of FGF23 to inhibit phosphate reabsorption in the proximal tubule&#46; However&#44; patients with more advanced CKD exhibited impaired urinary phosphate excretion despite extremely high FGF23 levels&#46;</p><p class="elsevierStylePara">Taken together&#44; it is suggested that in early stage of CKD&#44; serum FGF23 is elevated to maintain normal serum phosphate levels by promoting urinary phosphate excretion&#44; but in advanced stage&#44; overt phosphate loading may overcome such compensation for decreased GFR despite markedly elevated FGF23 levels&#44; which in turn results in decreased renal production of 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D&#44; possibly thereby worsening secondary hyperparathyroidism<span class="elsevierStyleSup">30</span>&#46; Another group further supported this hypothesis by elegantly showing that increased FGF23 was an independent predictor of decreased 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D levels and the effects of renal function and hyperphosphatemia on serum 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D levels were completely extinguished by adjusting for FGF23&#44; suggesting that FGF23 is a central factor in the early pathogenesis of secondary hyperparathyroidism<span class="elsevierStyleSup">13</span>&#46;</p><p class="elsevierStylePara">Of note&#44; a recent observational study have shown that in patients who are beginning hemodialysis treatment high FGF23 levels were associated with mortality independently of serum phosphate levels and other known risk factors<span class="elsevierStyleSup">31</span>&#46; Supposing that FGF23 may indicate phosphate retention even in patients with normophosphatemia&#44; its measurements may be useful to identify which of those patients might benefit from more aggressive phosphate management&#46; Whether such strategies for the control of phosphate homeostasis would prolong survival of CKD patients is worthy of further investigation&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">FGF23 AND SECONDARY HYPERPARATHYROIDISM IN CKD</span></p><p class="elsevierStylePara">Serum FGF23 levels are progressively increased as kidney function declines and are markedly elevated once on dialysis therapy<span class="elsevierStyleSup">32&#44;33</span>&#46; Such high levels of FGF23 may be due to persistent phosphate retention or&#160; hyperphosphatemia&#44; while active vitamin D therapy has also been shown to increase serum FGF23 levels in dialysis patients<span class="elsevierStyleSup">34</span>&#46; This observation was further supported by in vivo and in vitro studies showing that 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D directly increases the production of FGF23 by osteoblasts through the vitamin D-responsive elements present in the FGF23 promoter<span class="elsevierStyleSup">35</span>&#46; &#40;Figure 1&#41;</p><p class="elsevierStylePara">In this context&#44; it is an interesting finding that in dialysis patients with secondary hyperparathyroidism high FGF23 levels may predict the future development of refractory hyperparathyroidism<span class="elsevierStyleSup">32&#44;33</span>&#46; Although the mechanism of this finding remains unclear&#44; it is possible that chronic phosphate retention as reflected by elevated FGF23 levels maycontribute to further progression of parathyroid hyperplasia&#44; because high phosphate directly stimulates PTH secretion and parathyroid cell proliferation&#46; Another possibility is that high levels of FGF23 at baseline may be a consequence of prolonged active vitamin D administration for severe hyperparathyroidism<span class="elsevierStyleSup">35</span>&#44; which may be related to future resistance to vitamin D therapy&#46;</p><p class="elsevierStylePara">Besides the above-mentioned indirect effect of FGF23 on parathyroid function via inhibition of 1&#44;25&#40;OH&#41;<span class="elsevierStyleInf">2</span>D production&#44; the abundant expression of Klotho in the parathyroid suggests that FGF23 may directly affect parathyroid function<span class="elsevierStyleSup">25</span>&#46; In fact&#44; a recent study using rats with normal renal function has shown that FGF23 suppresses secretion of PTH in vivo and in vitro<span class="elsevierStyleSup">36</span>&#46; FGF23 also increases parathyroid 1&#945;-hydroxylase expression and partly thereby decreases secretion of PTH in primary cultures of bovine parathyroid cells<span class="elsevierStyleSup">37</span>&#46; Thus&#44; it is likely that FGF23 is a negative regulator of parathyroid function&#44; at least in normal physiology&#46; However&#44; in CKD patients with secondary hyperparathyroidism&#44; PTH secretion remains stimulated despite extremely high FGF23 levels<span class="elsevierStyleSup">32&#44;33</span>&#46; Such resistance of the parathyroid to high FGF23 levels in uremia should be investigated in future studies&#46;</p><p class="elsevierStylePara">Another issue of concern is a recent finding that PTH secretion is regulated in a Klotho- and&#160; Na<span class="elsevierStyleSup">&#43;</span>&#44;K<span class="elsevierStyleSup">&#43;</span>-ATPasedependent manner<span class="elsevierStyleSup">38</span>&#46; It is proposed that when extracellular calcium is low&#44; Na<span class="elsevierStyleSup">&#43;</span>&#44;K<span class="elsevierStyleSup">&#43;</span>-ATPase is quickly recruited to the plasma membrane and an electrochemical gradient created by increased Na<span class="elsevierStyleSup">&#43;</span>&#44;K<span class="elsevierStyleSup">&#43;</span>-ATPase may cause PTH release&#46; However&#44; it remains unclear how such a Klotho- and Na<span class="elsevierStyleSup">&#43;</span>&#44;K<span class="elsevierStyleSup">&#43;</span>-ATPasedependent PTH regulation interacts with the inhibitory effect of FGF23 on PTH secretion through Klotho-FGFR complexes&#46; Furthermore&#44; it is also a matter of concern whether such a complex mechanism is modulated in dialysis patients in whom phosphate retention is prevalent and hypocalcemic state is rare due to treatment with calcium-based phosphate binders and active vitamin D analogs&#46; Future studies should investigate the possible complex interaction between FGF23-&#44; Klotho- and Na<span class="elsevierStyleSup">&#43;</span>&#44;K<span class="elsevierStyleSup">&#43;</span>-ATPase-dependent pathways regulating PTH secretion and whether these complex mechanisms are modulated in the setting of CKD&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">CONCLUSION</span></p><p class="elsevierStylePara">The recent identification of FGF23 and Klotho as a physiological regulator of phosphate and vitamin D metabolism has considerably advanced our understanding of the mineral and bone disorder in CKD&#46; It is now clear that FGF23 plays a central role in the pathogenesis of altered mineral metabolism and secondary hyperparathyroidism in CKD patients&#46; FGF23 can be used not only as a biomarker for assessing phosphate retention but also as a predictor of mortality and future development of refractory hyperparathyroidism&#46; However&#44; the precise role of extremely elevated FGF23 levels in uremia still emains unclear&#44; especially as to its direct effect on parathyroid function&#46; Further elucidation of the FGF23- Klotho axis will help us to establish a more rational approach for the management of mineral and bone disorder that is associated with high burden of morbidity and mortality in CKD patients<span class="elsevierStyleSup">39&#44;40</span>&#46;</p><p class="elsevierStylePara"><a href="grande&#47;40818078&#95;f1&#95;pag394&#46;jpg" class="elsevierStyleCrossRefs"><img src="40818078_f1_pag394.jpg"></img></a></p><p class="elsevierStylePara">Figure 1&#46; </p>"
    "pdfFichero" => "P1-E23-S255-A408.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec434011"
          "palabras" => array:1 [
            0 => "Role of FGF23 in CKD"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec434012"
          "palabras" => array:1 [
            0 => "Role of FGF23 in CKD"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "El FGF23 es una hormona de reciente identificaci&#243;n que regula el metabolismo de los minerales y de la vitamina D&#46; En pacientes con insuficiencia renal cr&#243;nica &#40;IRC&#41;&#44; los niveles circulantes de FGF23 se elevan de forma progresiva para compensar la retenci&#243;n renal de fosfato persistente&#44; lo cual provoca una producci&#243;n renal reducida de 1&#44;25-dihidroxivitamina D y estimula&#44; por tanto&#44; la secreci&#243;n de la hormona paratifoidea&#46; Este hecho sugiere que su papel es crucial en la patog&#233;nesis de la homeostasis mineral alterada en la IRC&#46; Asimismo&#44; se ha demostrado recientemente que el FGF23 act&#250;a directamente en la gl&#225;ndula paratiroidea y media en la secreci&#243;n de la hormona paratiroidea en presencia del Klotho como cofactor&#44; aunque hasta el momento dichos efectos no se han confirmado en pacientes con IRC&#46; El FGF23 tambi&#233;n puede utilizarse como predictor de la mortalidad as&#237; como de un futuro desarrollo de hipertiroidismo refractario en pacientes sometidos a di&#225;lisis&#44; en los que los niveles de FGF23 son realmente elevados como reacci&#243;n al tratamiento de hiperfosfatemia y a la actividad de la vitamina D&#46; En este resumen breve se incluyen las aproximaciones m&#225;s recientes en cuanto al papel del FGF23 en la patog&#233;nesis de las alteraciones del metabolismo &#243;seo-mineral en la IRC&#46;"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara">FGF23 is a recently identified hormone regulating mineral and vitamin D metabolism&#46; In patients with chronic kidney disease &#40;CKD&#41;&#44; circulating FGF23 levels are progressively elevated to compensate for persistent phosphate retention&#44; which result in reduced renal production of 1&#44;25-dihydroxyvitamin D and thereby stimulate secretion of parathyroid hormone&#44; suggesting its critical role in the pathogenesis of altered mineral homeostasis in CKD&#46; Furthermore&#44; it has recently been shown that FGF23 directly acts on parathyroid gland and mediate secretion of parathyroid hormone in the presence of Klotho as a cofactor&#44; although such effects are not yet confirmed in patients with CKD&#46; FGF23 can also be used as a predictor of mortality as well as future development of refractory hyperparathyroidism in patients undergoing dialysis therapy&#44; where FGF23 levels are markedly elevated in response to hyperphosphatemia and active vitamin D treatment&#46; This brief review summarizes recent insights into the role of FGF23 in the pathogenesis of mineral and bone disorders in CKD&#46;</p>"
      ]
    ]
    "multimedia" => array:1 [
      0 => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "408527_fig1.jpg"
            "Alto" => 499
            "Ancho" => 710
            "Tamanyo" => 31185
          ]
        ]
      ]
    ]
    "bibliografia" => array:1 [
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:40 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Moe S, Drueke T, Cunningham J, et al. Definition, evaluation and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945-1953."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15615819" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Menon V, Greene T, Pereira AA, et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005;46:455-63. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16129207" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-33. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16246962" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000;11:1141-52. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10820180" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2002;283:F367-76 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12167586" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int 2006;70(Suppl 102):S3-7."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11062477" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001;98:6500-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11344269" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005;90:1519-24. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15613425" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14633152" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Shigematsu T, Yamashita T, Fukumoto S, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney 2004;44:250-6."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gutiérrez O, Isakova T, Rhee E, et al: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-15.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/15917335" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006;291:E38-49. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16449303" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Endocrine functions of bone in mineral metabolism regulation. Quarles LD. J Clin Invest 2008;118:3820-8."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11032749" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12711740" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006;38:1310-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17033621" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003;112:683-92. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12952917" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15040831" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004;145:3087¨C3094 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15319355" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Bai X, Miao D, Li J, et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004;145:5269-79. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15284207" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14966565" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S0168851013000432"
                          "estado" => "S300"
                          "issn" => "01688510"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 2008;237:18-27. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18058912" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17086194" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2006;281:6120-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16436388" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib27"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9363890" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib28"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Liu S, Vierthaler L, Tang W, et al. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 2008;19:2342-50. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18753255" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib29"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with endstage renal disease on hemodialysis. Kidney Int 2004;65:1943-6 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15086938" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib30"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF23 in CKD. Nephrol Dial Transplant 2005;20:1295-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15840677" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib31"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gutiérrez OM, Mannstadt M, Isakova T, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-94"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S0168851013001589"
                          "estado" => "S300"
                          "issn" => "01688510"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib32"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor- 23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005;67:1171-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15698459" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib33"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kazama JJ, Sato F, Omori K, et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005;67:1120-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15698453" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib34"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nishi H, Nii-Kono T, Nakanishi S, et al. Intravenous calcitriol therapy increases serum concentration of fibroblast growth factor 23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005;101:c94-c99. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15956805" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib35"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;17:1305-15. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16597685" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib36"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ben Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17992255" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib37"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007;195:125-31. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17911404" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib38"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Imura A, Tsuji Y, Murata M, et al. ¿-Klotho as a regulator of calcium homeostasis. Science 2007;316:1615-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17569864" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib39"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15284307" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib40"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18514987" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/0000002900000005/v0_201502091404/X0211699509003608/v0_201502091404/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35404"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Revisiones cortas"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/0000002900000005/v0_201502091404/X0211699509003608/v0_201502091404/en/P1-E23-S255-A408.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509003608?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 8 13 21
2024 Octubre 55 35 90
2024 Septiembre 73 34 107
2024 Agosto 81 59 140
2024 Julio 50 36 86
2024 Junio 59 31 90
2024 Mayo 70 26 96
2024 Abril 55 33 88
2024 Marzo 59 24 83
2024 Febrero 53 34 87
2024 Enero 45 25 70
2023 Diciembre 36 24 60
2023 Noviembre 57 29 86
2023 Octubre 39 29 68
2023 Septiembre 52 30 82
2023 Agosto 46 16 62
2023 Julio 41 27 68
2023 Junio 39 16 55
2023 Mayo 49 38 87
2023 Abril 23 14 37
2023 Marzo 21 27 48
2023 Febrero 31 33 64
2023 Enero 42 28 70
2022 Diciembre 39 40 79
2022 Noviembre 50 33 83
2022 Octubre 95 54 149
2022 Septiembre 37 32 69
2022 Agosto 42 56 98
2022 Julio 34 46 80
2022 Junio 47 34 81
2022 Mayo 37 36 73
2022 Abril 52 36 88
2022 Marzo 52 53 105
2022 Febrero 41 51 92
2022 Enero 27 36 63
2021 Diciembre 36 44 80
2021 Noviembre 30 41 71
2021 Octubre 39 56 95
2021 Septiembre 29 38 67
2021 Agosto 51 27 78
2021 Julio 53 39 92
2021 Junio 47 40 87
2021 Mayo 37 23 60
2021 Abril 69 56 125
2021 Marzo 55 25 80
2021 Febrero 81 19 100
2021 Enero 58 31 89
2020 Diciembre 36 13 49
2020 Noviembre 44 18 62
2020 Octubre 35 12 47
2020 Septiembre 35 25 60
2020 Agosto 55 17 72
2020 Julio 75 12 87
2020 Junio 61 24 85
2020 Mayo 58 22 80
2020 Abril 53 28 81
2020 Marzo 45 21 66
2020 Febrero 75 24 99
2020 Enero 90 36 126
2019 Diciembre 96 34 130
2019 Noviembre 60 25 85
2019 Octubre 19 14 33
2019 Septiembre 53 14 67
2019 Agosto 19 15 34
2019 Julio 52 32 84
2019 Junio 30 30 60
2019 Mayo 28 45 73
2019 Abril 108 27 135
2019 Marzo 43 22 65
2019 Febrero 25 30 55
2019 Enero 37 27 64
2018 Diciembre 66 32 98
2018 Noviembre 77 17 94
2018 Octubre 74 9 83
2018 Septiembre 72 9 81
2018 Agosto 44 13 57
2018 Julio 49 13 62
2018 Junio 40 11 51
2018 Mayo 50 14 64
2018 Abril 63 8 71
2018 Marzo 47 12 59
2018 Febrero 40 3 43
2018 Enero 36 6 42
2017 Diciembre 41 10 51
2017 Noviembre 45 13 58
2017 Octubre 49 10 59
2017 Septiembre 51 19 70
2017 Agosto 56 19 75
2017 Julio 39 18 57
2017 Junio 59 11 70
2017 Mayo 59 23 82
2017 Abril 35 15 50
2017 Marzo 38 14 52
2017 Febrero 116 20 136
2017 Enero 62 13 75
2016 Diciembre 97 11 108
2016 Noviembre 118 6 124
2016 Octubre 167 16 183
2016 Septiembre 166 16 182
2016 Agosto 239 11 250
2016 Julio 174 8 182
2016 Junio 133 0 133
2016 Mayo 153 0 153
2016 Abril 103 0 103
2016 Marzo 104 0 104
2016 Febrero 124 0 124
2016 Enero 118 0 118
2015 Diciembre 126 0 126
2015 Noviembre 114 0 114
2015 Octubre 88 0 88
2015 Septiembre 88 0 88
2015 Agosto 75 0 75
2015 Julio 64 0 64
2015 Junio 45 0 45
2015 Mayo 81 0 81
2015 Abril 21 0 21
2015 Febrero 2836 0 2836
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?